Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Zhejiang Cancer Hospital
The PI3K/AKT/mTOR pathway is frequently altered in breast cancer. Everolimus is a selective inhibitor of mammalian target of Rapamycin (mTOR).The benefit of everolimus in metastatic breast cancer patients with PI3K/AKT/mTOR mutations remains unclear, especially in TNBC patients. The study aimed to investigate the efficacy of the everolimus-containing chemotherapy in metastatic breast cancer patients with PI3K/AKT/mTOR mutations.
14 cases of HER2- metastatic breast cancer participants with PI3K/AKT/mTOR mutations treated with everolimus-containing chemotherapy were retrospectively analyzed.The genetic profile in PI3K/AKT/mTOR pathway was studied.
Age
29–66
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
1. Patients with HER2- metastatic breast cancer
2. Patients with PI3K/AKT/mTOR mutation
You may not be if
1. Patients treated with endocrinotherapy and everolimus.
2. The efficacy evaluation could not be available.
Clareo Health | Efficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations Study
